Scinai expands CDMO business with $5.1 million development and clinical manufacturing agreement

SCNI•2026-10-13

Scinai Immunotherapeutics signed a $5.1 million development and clinical manufacturing agreement, with work supporting development in 2026 and clinical manufacturing in 2027. Additional clinical manufacturing in late 2027 through the first half of 2028 has an indicative value of $5.85 million.

1. Agreement details

Scinai Immunotherapeutics said the agreement supports development in 2026 and clinical manufacturing in 2027. Potential additional clinical manufacturing from late 2027 through the first half of 2028 has an indicative value of $5.85 million.

Scinai expands CDMO business with $5.1 million development and clinical manufacturing agreement

1. Agreement details

Related News

MBX Biosciences to present at Guggenheim Healthcare Innovation Conference

Citi profit jumps 40% with higher investment banking, services and wealth revenue

aTyr Pharma reports paper showing anti-fibrotic effects of ATYR0101 in lung model

Manulife targets $1 billion in cumulative enterprise AI value by 2027 with global platform rollout

Iveda, GlobalMed to host live IvedaAir unmanned helicopter flight demo for government, defense stakeholders